Ken Griffin Sellas Life Sciences Group, Inc. Put Options Transaction History

Citadel Advisors LLC

12 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2025 Aug 14, 2025	BUY	$1.04 - $2.19 $6,968 - $14,673	6,700 Added 25.48%	33,000 $72,000
Q1 2025 May 15, 2025	SELL	$0.92 - $1.62 $2,208 - $3,888	-2,400 Reduced 8.36%	26,300 $28,000
Q4 2024 Feb 14, 2025	SELL	$0.84 - $1.35 $38,640 - $62,100	-46,000 Reduced 61.58%	28,700 $28,000
Q3 2024 Nov 14, 2024	BUY	$1.08 - $1.39 $68,040 - $87,570	63,000 Added 538.46%	74,700 $93,000
Q2 2024 Aug 14, 2024	BUY	$1.06 - $1.63 $10,706 - $16,463	10,100 Added 631.25%	11,700 $13,000
Q1 2024 May 15, 2024	SELL	$0.51 - $1.55 $6,987 - $21,235	-13,700 Reduced 89.54%	1,600 $1,000
Q4 2023 Feb 14, 2024	SELL	$0.88 - $1.57 $1,584 - $2,826	-1,800 Reduced 10.53%	15,300 $16,000
Q3 2023 Nov 14, 2023	SELL	$1.42 - $1.83 $11,218 - $14,457	-7,900 Reduced 31.6%	17,100 $28,000
Q2 2023 Aug 14, 2023	SELL	$1.35 - $1.8 $30,915 - $41,220	-22,900 Reduced 47.81%	25,000 $39,000
Q1 2023 May 15, 2023	BUY	$1.18 - $3.86 $40,356 - $132,012	34,200 Added 249.64%	47,900 $68,000
Q4 2022 Feb 14, 2023	BUY	$1.8 - $5.41 $5,400 - $16,230	3,000 Added 28.04%	13,700 $32,000
Q3 2022 Nov 14, 2022	SELL	$2.02 - $3.38 $202 - $338	-100 Reduced 0.93%	10,700 $22,000

22.6M

1.3M

59.3K

Ticker SLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,551,900
Market Cap $33.1M
Description
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.